|

Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

RECRUITINGSponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Actively Recruiting
SponsorBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Started2023-08-25
Est. completion2024-08-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06570980

Summary

The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* New onset type2 diabetes mellitus diagnosed for 2 -5 years.
* Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
* Age 18 years or above.
* Both male and female.
* Provided written informed consent.

Exclusion Criteria:

* Unwillingness to participate or unwillingness to give written informed consent.
* Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.
* Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
* Diabetes related complications at the time of diagnosis.

Conditions2

DiabetesType 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.